)News & Events:
  • STAR Spotlight: Leading Pharma Companies in Public Policy more>
  • STAR Report: Keys to Effective Advocacy Relations more>
  • STAR Spotlight: Leading Companies in Advocacy Relations 2014 more>
  • Spring STAR Surveys are in the field! more>
  • STAR Fall 2013 Results Webcast: Enhancing Relationships with Pharmaceutical Companies more>
  • STAR Spotlight: Best practice in advocacy relations depends on the Therapeutic Area more>
  • Web seminar: Measuring your advocacy efforts: The STAR Report 2013 findings more>
  • STAR Spotlight: How can you enhance your relationship with advocacy groups? more>
  • STAR Spotlight: Advocates’ Role in Key Policy and Access Issues more>
  • STAR Spotlight: Working with Advocacy Groups in Coalitions more>

The STAR Report

Competitive Benchmarking and Strategic Insights in Advocacy Relations.

The STAR report is a market research offering from The Brooks Group and Mark Krueger & Associates that has provided competitive benchmarking and strategic insights in advocacy relations since 2010. Updated in the fall and spring of each year, the insights elicited from this report can help companies:

  • Uncover emerging policy, advocacy, and market trends impacting their companies.
  • Measure advocacy efforts effectiveness and improve or enhance approach based on rankings.
  • Determine how to engage with advocacy groups and managed care organizations around access issues.
  • Identify ways to enhance support and partnership efforts with advocacy groups.
  • Assess opportunities to have “a seat at the table” in policy issues impacting advocacy group partners.

“Finally, two credible organizations [The Brooks Group and Mark Krueger & Associates] have partnered together to provide deeper insights into advocacy activities to help us target and measure the effectiveness of our activities moving forward.”

– Vice President, Large Pharma Company

Why STAR?

The STAR Report will help you understand emerging policy and advocacy trends, enabling you to quickly and efficiently develop, commercialize, differentiate, and secure reimbursement for your products.

1

Healthcare policy is changing dramatically, and the effects of the changes will be felt across many factors, including reimbursment and patient advocacy.

2

The STAR Report puts patient advocacy relations in the forefront and will help pharmaceutical and biotech executives identify how their companies are impacted by the external environment.

3

STAR research will help them become better prepared to take advantage of - and respond quickly to - the opportunities and threats impacting their business strategy.

Research Highlights

<

Which companies lead in advocacy relations?

For the second year, Roche/Genentech and Pfizer were nominated as the top two companies providing support to advocacy organizations across all disease states.

Read More)

Leading Companies in Advocacy Relations

Working with advocacy organizations is an effective way for pharmaceutical and biotech companies to help advance their goals and initiatives, while meeting patients’ needs. Advocacy groups are actively partnering with industry in a variety of ways to support their missions and maximize impact. The question is, which tactics are most impactful and which companies are getting advocacy ‘right’?  The STAR Report reveals which companies are seen as most effective in their advocacy relations efforts and identifies ways to enhance partnerships with advocacy groups.

The 2013 STAR Spring report shares insights from 101 patient advocacy groups and professional associations across 15 therapeutic areas.  The data reveals:

  • For the second year, Roche/Genentech and Pfizer were nominated as the top two companies providing support to advocacy organizations across all disease states.  Groups appreciate Genentech’s forward thinking approach and long-standing relationships. Pfizer’s personnel are praised for their in-depth knowledge and networking abilities.
  • Novartis was new to the top rankings in 2013, moving to third from seventh in 2012.
  • How other companies performed and whether they moved up or down in rankings from previous years.
  • Which companies lead in specific therapeutic areas.
  • Which companies have the best corporate image among advocacy groups and why.
  • What types of support are groups most interested in receiving from industry partners. Understanding their priorities helps companies target and maximize support.

What healthcare policy issues are of most interest to advocacy groups?

Across some of the major components of healthcare reform, STAR data reveal that groups have the most interest and involvement in state exchanges and their essential health benefits (EHB) packages.

Read More)

Engaging with Advocacy Groups on Healthcare Policy 

Patient advocacy groups and professional associations play an important role in shaping healthcare policy, but what policy issues are of greatest interest to groups and how are they working with industry to achieve their goals?

The 2013 STAR Report provides insights into the policy activities and interests of 101 patient advocacy groups and professional associations across 15 therapeutic areas.  Across some of the major components of healthcare reform, the data reveal that groups have the most interest and involvement in state exchanges and their essential health benefits (EHB) packages.  Additionally, Johnson & Johnson, GSK, and Pfizer are recognized as leaders in working with advocacy groups and/or other healthcare entities to ensure that essential health benefits packages meet patients’ needs. The report also reveals:

  • Almost three-quarters of advocacy groups attended policy forums sponsored by industry in the past year, with most attending more than one.
  • Policy forum topics of most interest to advocacy groups are quality of care, followed by the Patient-Centered Outcome Research Institute (PCORI) and Comparative Effectiveness Research (CER).
  • Which pharmaceutical companies host the best policy forums.
  • What topics are covered most frequently at industry-hosted policy forums.
  • What elements make an industry-hosted policy forum successful.
  • What are the biggest mistakes companies make when hosting policy forums.

MCOs and Advocacy Groups

STAR data reveal that treatment guidelines, co-pay assistance programs, and comparative effectiveness research (CER) are the areas in which MCOs see the best opportunities for working with advocacy groups.

Read More)

MCO Engagement with Advocacy Groups

Managed care organizations (MCOs) often work with patient and professional groups to development guidelines for appropriate treatment coverage and help educate members on issues such as disease prevention, treatment information, and medication adherence.  Every fall, STAR surveys MCOs to determine how they are working with advocacy groups and where they see the greatest potential for expanding their relationships.  These findings can help pharmaceutical and biotech companies understand how they might collaborate with advocacy groups and MCOs on joint initiatives.

 

Data from the Fall 2012 STAR Report reveals:

  • Treatment guidelines, co-pay assistance programs, and comparative effectiveness research (CER) are the areas in which MCOs see the best opportunities for working with advocacy groups.
  • Approximately one-third of MCOs work directly with advocacy groups.
  • The scope of MCO interaction with advocacy groups and which functions within MCOs are interacting with groups.
  • Which therapeutic areas most frequently attract MCO – advocacy group collaboration.
  • How MCOs engage with advocacy groups on specific policy activities.
  • Which healthcare policy issues are of greatest concern to MCOs.
  • Key sources of information utilized by MCOs to stay abreast of healthcare policy issues.

What is considered best practice in advocacy relations?

According to patient advocacy groups surveyed by STAR, factors that indicate best in class advocacy programs supported by industry are those that focus on public policy, engage groups in drug development, and increase awareness of their causes.

Read More)

Best Practice Case Studies in Advocacy Relations

Each year, The STAR Report includes case studies that provide pharmaceutical and biotech companies with insights into peer companies’ innovative initiatives with advocacy groups. These studies reveal the elements critical to a successful partnership, examine the risks and challenges faced, and provide insight into the value of a partnership.

With your subscription to STAR, you’ll have access to these best practice case studies.  For example, 2011 STAR Case Studies described:

  • How the American Heart Association/American Stroke Association joined forces with Bristol-Myers Squibb and Sanofi in a national stroke awareness campaign.
  • How a coalition of four patient groups collaborated with Amgen in a unified program to provide cancer support from prevention to survivorship.
  • How Bristol-Myers Squibb supported AIDS Alabama advocacy initiatives in a critical environment.
>

Research Findings

  • Which companies lead in advocacy relations?

    For the second year, Roche/Genentech and Pfizer were nominated as the top two companies providing support to advocacy organizations across all disease states.

    Read More)

    Leading Companies in Advocacy Relations

    Working with advocacy organizations is an effective way for pharmaceutical and biotech companies to help advance their goals and initiatives, while meeting patients’ needs. Advocacy groups are actively partnering with industry in a variety of ways to support their missions and maximize impact. The question is, which tactics are most impactful and which companies are getting advocacy ‘right’?  The STAR Report reveals which companies are seen as most effective in their advocacy relations efforts and identifies ways to enhance partnerships with advocacy groups.

    The 2013 STAR Spring report shares insights from 101 patient advocacy groups and professional associations across 15 therapeutic areas.  The data reveals:

    • For the second year, Roche/Genentech and Pfizer were nominated as the top two companies providing support to advocacy organizations across all disease states.  Groups appreciate Genentech’s forward thinking approach and long-standing relationships. Pfizer’s personnel are praised for their in-depth knowledge and networking abilities.
    • Novartis was new to the top rankings in 2013, moving to third from seventh in 2012.
    • How other companies performed and whether they moved up or down in rankings from previous years.
    • Which companies lead in specific therapeutic areas.
    • Which companies have the best corporate image among advocacy groups and why.
    • What types of support are groups most interested in receiving from industry partners. Understanding their priorities helps companies target and maximize support.
  • What healthcare policy issues are of most interest to advocacy groups?

    Across some of the major components of healthcare reform, STAR data reveal that groups have the most interest and involvement in state exchanges and their essential health benefits (EHB) packages.

    Read More)

    Engaging with Advocacy Groups on Healthcare Policy 

    Patient advocacy groups and professional associations play an important role in shaping healthcare policy, but what policy issues are of greatest interest to groups and how are they working with industry to achieve their goals?

    The 2013 STAR Report provides insights into the policy activities and interests of 101 patient advocacy groups and professional associations across 15 therapeutic areas.  Across some of the major components of healthcare reform, the data reveal that groups have the most interest and involvement in state exchanges and their essential health benefits (EHB) packages.  Additionally, Johnson & Johnson, GSK, and Pfizer are recognized as leaders in working with advocacy groups and/or other healthcare entities to ensure that essential health benefits packages meet patients’ needs. The report also reveals:

    • Almost three-quarters of advocacy groups attended policy forums sponsored by industry in the past year, with most attending more than one.
    • Policy forum topics of most interest to advocacy groups are quality of care, followed by the Patient-Centered Outcome Research Institute (PCORI) and Comparative Effectiveness Research (CER).
    • Which pharmaceutical companies host the best policy forums.
    • What topics are covered most frequently at industry-hosted policy forums.
    • What elements make an industry-hosted policy forum successful.
    • What are the biggest mistakes companies make when hosting policy forums.
  • MCOs and Advocacy Groups

    STAR data reveal that treatment guidelines, co-pay assistance programs, and comparative effectiveness research (CER) are the areas in which MCOs see the best opportunities for working with advocacy groups.

    Read More)

    MCO Engagement with Advocacy Groups

    Managed care organizations (MCOs) often work with patient and professional groups to development guidelines for appropriate treatment coverage and help educate members on issues such as disease prevention, treatment information, and medication adherence.  Every fall, STAR surveys MCOs to determine how they are working with advocacy groups and where they see the greatest potential for expanding their relationships.  These findings can help pharmaceutical and biotech companies understand how they might collaborate with advocacy groups and MCOs on joint initiatives.

     

    Data from the Fall 2012 STAR Report reveals:

    • Treatment guidelines, co-pay assistance programs, and comparative effectiveness research (CER) are the areas in which MCOs see the best opportunities for working with advocacy groups.
    • Approximately one-third of MCOs work directly with advocacy groups.
    • The scope of MCO interaction with advocacy groups and which functions within MCOs are interacting with groups.
    • Which therapeutic areas most frequently attract MCO – advocacy group collaboration.
    • How MCOs engage with advocacy groups on specific policy activities.
    • Which healthcare policy issues are of greatest concern to MCOs.
    • Key sources of information utilized by MCOs to stay abreast of healthcare policy issues.
  • What is considered best practice in advocacy relations?

    According to patient advocacy groups surveyed by STAR, factors that indicate best in class advocacy programs supported by industry are those that focus on public policy, engage groups in drug development, and increase awareness of their causes.

    Read More)

    Best Practice Case Studies in Advocacy Relations

    Each year, The STAR Report includes case studies that provide pharmaceutical and biotech companies with insights into peer companies’ innovative initiatives with advocacy groups. These studies reveal the elements critical to a successful partnership, examine the risks and challenges faced, and provide insight into the value of a partnership.

    With your subscription to STAR, you’ll have access to these best practice case studies.  For example, 2011 STAR Case Studies described:

    • How the American Heart Association/American Stroke Association joined forces with Bristol-Myers Squibb and Sanofi in a national stroke awareness campaign.
    • How a coalition of four patient groups collaborated with Amgen in a unified program to provide cancer support from prevention to survivorship.
    • How Bristol-Myers Squibb supported AIDS Alabama advocacy initiatives in a critical environment.

The Benefits of STAR

STAR Report survey findings will identify

Short and long-term goals within specific
advocacy communities.
Which companies are evaluated as
the best overall.
Which companies are most respected by
patient and professional groups.
How advocacy groups address access and reimbursement.
Which pharma company’s public
policy activities are the most effective. Request More Information)
Which companies provide value-added
programs that are most appreciated
by advocacy groups. Download The Brochure)

Methodology

Expert Analysis

Our team of advocacy and health care industry experts reviews and analyzes research results to synthesize key findings that will inform future programming and policy work within major pharmaceutical and biotech companies.

More Details on STAR Methodology)

More Info on STAR Methodology

Therapeutic Areas Include:

  • Cardiovascular
  • Diabetes/Metabolic Syndrome
  • Hematology
  • HIV/AIDS
  • Immunology
  • Infectious Disease
  • Mental Health
  • Musculoskeletal Conditions
  • Nephrology
  • Neurology
  • Oncology
  • Ophthalmology
  • Respiratory
  • Urology/Men’s Health
  • Women’s Health

Panelists include:

  • Presidents, Executive Directors, Policy and Programming Staff of leading national organizations
    • Patient Advocacy Groups
    • Professional Associations
    • Consumer Groups

STAR includes a separate survey sent to non-disease specific advocacy groups, including those that focus on rare disorders.

Primary Research: Online, Quantitative surveys

Targeted advocacy organizations, representing a wide range of therapeutic areas and constituencies, are surveyed to uncover organizational priorities and to rate current industry partners and support. Each research cycle, advocates are also surveyed on key topical areas such as policy activities, engaging with pharma on clinical trials and patient registries, and what is means for a company to be patient-centric.

More Details on STAR Methodology)

More Info on STAR Methodology

Therapeutic Areas Include:

  • Cardiovascular
  • Diabetes/Metabolic Syndrome
  • Hematology
  • HIV/AIDS
  • Immunology
  • Infectious Disease
  • Mental Health
  • Musculoskeletal Conditions
  • Nephrology
  • Neurology
  • Oncology
  • Ophthalmology
  • Respiratory
  • Urology/Men’s Health
  • Women’s Health

Panelists include:

  • Presidents, Executive Directors, Policy and Programming Staff of leading national organizations
    • Patient Advocacy Groups
    • Professional Associations
    • Consumer Groups

STAR includes a separate survey sent to non-disease specific advocacy groups, including those that focus on rare disorders.

Primary Research: In-depth Interviews

Comprehensive interviews with selected respondents dive deeper into support needs, existing programs, and additional high priority topics.

More Details on STAR Methodology)

More Info on STAR Methodology

Therapeutic Areas Include:

  • Cardiovascular
  • Diabetes/Metabolic Syndrome
  • Hematology
  • HIV/AIDS
  • Immunology
  • Infectious Disease
  • Mental Health
  • Musculoskeletal Conditions
  • Nephrology
  • Neurology
  • Oncology
  • Ophthalmology
  • Respiratory
  • Urology/Men’s Health
  • Women’s Health

Panelists include:

  • Presidents, Executive Directors, Policy and Programming Staff of leading national organizations
    • Patient Advocacy Groups
    • Professional Associations
    • Consumer Groups

STAR includes a separate survey sent to non-disease specific advocacy groups, including those that focus on rare disorders.

> <

Interested in the STAR Report?

Advocacy Groups can be Powerful Partners

Tap into that potential with insights to help make the most of your company’s collaboration with advocacy organizations.  Understand what is working, what is needed, and how to maximize the impact of your involvement with these important stakeholders.

Delivery

Research Agenda

Spring 2016

  • Management Summary
  • Leading Pharmaceutical/Biotech Companies in Patient Advocacy Relations
  • Longitudinal Assessment: 2010 – 2016 Comparison of Leading Companies in Advocacy Relations
  • Leading Pharmaceutical/Biotech Companies in Professional Group Relations
  • Leading Pharmaceutical/Biotech Companies in Advocacy Relations by Therapeutic Area
  • Making Patient Centricity a Reality: Patient and Pharma Perspectives
  • Pharma Insights: Industry Engagement in Advocacy, Policy, and Access

Fall 2016

  • Management Summary
  • Leading Pharmaceutical/Biotech Companies in Public Policy (Patient and Professional)
  • Longitudinal Assessment: 2010-2016 Comparison of Leading Companies in Public Policy
  • Leading Pharmaceutical/Biotech Companies in Public Policy by Therapeutic Area
  • State Advocacy Relations: Working at the State Level
  • Tackling Barriers to Patient Access: Patient and Payer Perspectives

About Us

The Brooks Group and Mark Krueger & Associates, Inc.

The Brooks Group

Established in 1996, The Brooks Group is a highly specialized consulting firm whose mission is to enhance the impact of sales and marketing professionals and their processes in pharmaceuticals, biotech, and healthcare. We accomplish this mission through strategic management consulting, syndicated and customized market research, highly customized sales training and development, and thought leader development.

Mark Krueger & Associates

Since 1995, Mark Krueger & Associates, Inc. (MK&A) has been a leader in healthcare constituency relations. MK&A’s clients include major pharmaceutical companies as well as biotechnology, device, and diagnostic companies. Our focus is on helping our clients establish and enhance partnerships with the diverse groups that influence the success of their products.

Contact Us

The Brooks Group

Karen Ernst, MBA

+1 610 235 4078

karen.ernst@brooksgroupinc.biz

301 Lacey Street, 1st Floor

West Chester, PA

19382

www.thebrooksgrouponline.com

Mark Krueger & Associates, Inc.

Sharon Dion, MBA, MA

+1 212 620 2774

sdion@mkanda.com

521 Fifth Avenue, 27th Floor

New York, NY

10175

www.kruegerandassociates.com